Clinical Outcomes After Anterior Cruciate Ligament Injury: Panther Symposium ACL Injury Clinical Outcomes Consensus Group by Svantesson, Eleonor et al.
Western University 
Scholarship@Western 
Bone and Joint Institute 
7-1-2020 
Clinical Outcomes After Anterior Cruciate Ligament Injury: 
Panther Symposium ACL Injury Clinical Outcomes Consensus 
Group 
Eleonor Svantesson 
UPMC Sports Medicine 
Eric Hamrin Senorski 
UPMC Sports Medicine 
Kate E. Webster 
UPMC Sports Medicine 
Jón Karlsson 
UPMC Sports Medicine 
Theresa Diermeier 
UPMC Sports Medicine 
See next page for additional authors 
Follow this and additional works at: https://ir.lib.uwo.ca/boneandjointpub 
 Part of the Medicine and Health Sciences Commons 
Citation of this paper: 
Svantesson, Eleonor; Hamrin Senorski, Eric; Webster, Kate E.; Karlsson, Jón; Diermeier, Theresa; Rothrauff, 
Benjamin B.; Meredith, Sean J.; Rauer, Thomas; Irrgang, James J.; Spindler, Kurt P.; Ma, C. Benjamin; 
Musahl, Volker; the Panther Symposium ACL Injury Clinical Outcomes Consensus Group; Fu, Freddie H.; 
Ayeni, Olufemi R.; Della Villa, Francesco; Della Villa, Stefano; Dye, Scott; Ferretti, Mario; Getgood, Alan; 
Järvelä, Timo; Kaeding, Christopher C.; Kuroda, Ryosuke; Lesniak, Bryson; Marx, Robert G.; Maletis, 
Gregory B.; Pinczewski, Leo; Ranawat, Anil; Reider, Bruce; Seil, Romain; van Eck, Carola; Wolf, Brian R.; and 
Yung, Patrick, "Clinical Outcomes After Anterior Cruciate Ligament Injury: Panther Symposium ACL Injury 
Clinical Outcomes Consensus Group" (2020). Bone and Joint Institute. 1478. 
https://ir.lib.uwo.ca/boneandjointpub/1478 
Authors 
Eleonor Svantesson, Eric Hamrin Senorski, Kate E. Webster, Jón Karlsson, Theresa Diermeier, Benjamin B. 
Rothrauff, Sean J. Meredith, Thomas Rauer, James J. Irrgang, Kurt P. Spindler, C. Benjamin Ma, Volker 
Musahl, the Panther Symposium ACL Injury Clinical Outcomes Consensus Group, Freddie H. Fu, Olufemi 
R. Ayeni, Francesco Della Villa, Stefano Della Villa, Scott Dye, Mario Ferretti, Alan Getgood, Timo Järvelä, 
Christopher C. Kaeding, Ryosuke Kuroda, Bryson Lesniak, Robert G. Marx, Gregory B. Maletis, Leo 
Pinczewski, Anil Ranawat, Bruce Reider, Romain Seil, Carola van Eck, Brian R. Wolf, and Patrick Yung 
This conference proceeding is available at Scholarship@Western: https://ir.lib.uwo.ca/boneandjointpub/1478 
Consensus Statement
Clinical Outcomes After Anterior Cruciate
Ligament Injury
Panther Symposium ACL Injury Clinical Outcomes
Consensus Group
Eleonor Svantesson,* MD, Eric Hamrin Senorski, PT, PhD, Kate E. Webster, PhD,
Jón Karlsson, MD, PhD, Theresa Diermeier, MD, Benjamin B. Rothrauff, MD,
Sean J. Meredith, MD, Thomas Rauer, MD, James J. Irrgang, PT, PhD, FAPTA,
Kurt P. Spindler, MD, C. Benjamin Ma, MD, Volker Musahl, MD,
and the Panther Symposium ACL Injury Clinical Outcomes Consensus Group
Investigation performed at UPMC Freddie Fu Sports Medicine Center,
Pittsburgh, Pennsylvania, USA
A stringent outcome assessment is a key aspect of establishing evidence-based clinical guidelines for anterior cruciate ligament
(ACL) injury treatment. To establish a standardized assessment of clinical outcome after ACL treatment, a consensus meeting
including a multidisciplinary group of ACL experts was held at the ACL Consensus Meeting Panther Symposium, Pittsburgh,
Pennsylvania, USA, in June 2019. The aim was to establish a consensus on what data should be reported when conducting an ACL
outcome study, what specific outcome measurements should be used, and at what follow-up time those outcomes should be
assessed. The group reached consensus on 9 statements by using a modified Delphi method. In general, outcomes after ACL
treatment can be divided into 4 robust categories: early adverse events, patient-reported outcomes (PROs), ACL graft failure/
recurrent ligament disruption, and clinical measures of knee function and structure. A comprehensive assessment after ACL
treatment should aim to provide a complete overview of the treatment result, optimally including the various aspects of outcome
categories. For most research questions, a minimum follow-up of 2 years with an optimal follow-up rate of 80% is necessary to
achieve a comprehensive assessment. This should include clinical examination, any sustained reinjuries, validated knee-specific
PROs, and health-related quality of life questionnaires. In the midterm to long-term follow-up, the presence of osteoarthritis should
be evaluated. This consensus paper provides practical guidelines for how the aforementioned entities of outcomes should be
reported and suggests the preferred tools for a reliable and valid assessment of outcome after ACL treatment.
Keywords: reconstruction; patient-reported outcome; laxity; osteoarthritis; consensus statement
The evolution of evidence-based medicine is considered one
of the most important paradigm shifts in modern medi-
cine,28,104 for which conduction of high-quality research is
fundamental. Anterior cruciate ligament (ACL) injuries are
among the most studied in the field of orthopaedics and
sports medicine, with over 25,000 publications available
in the PubMed database up to mid-2019. Despite ongoing
research and advancements in treatment regimens for ACL
injuries over the past decades, the goal of restored knee
function and preserved long-term knee-related health
remains a challenge. Reinjury rates are high, especially
among the young and active,117,120 and the high rate of
subsequent development of posttraumatic osteoarthritis
(OA) is worrying.1,21,81,86 In the best interest of our
patients, a deepened understanding of how to optimize an
individualized approach to ACL injury treatment is needed.
One important part of this process is to strive for a stan-
dardized and homogeneous research methodology of clini-
cal outcome assessment after ACL treatment.
A rigorous outcome assessment after ACL injury is a key
aspect for determining the clinical efficacy and effective-
ness of treatment. It can also identify modifiable and non-
modifiable predictors of good and poor outcome, which
provide valuable insights for the patient’s prognosis and
should be discussed in the context of shared decision
making for the treatment choice after ACL injury. More-
over, a standardized outcome assessment and reporting of
data are required for comparisons between studies and for
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pooling of data in meta-analyses to provide the highest level
of evidence-based medicine. Current literature related to
ACL treatment is limited by the fact that no consensus
exists on how to assess and report clinical outcome. There
is a wide range of validated outcome assessment tools for
ACL treatment. Although each of these outcome measures
may offer certain advantages and the patient’s perspective
of outcome should always be evaluated, caution must be
taken to ensure that outcome measures accurately capture
patient-centered and clinically relevant outcomes for an
ACL-injured patient. Another debated area in ACL out-
come assessment is the use of ACL graft failure as an end-
point for research. This is highly relevant to the patient;
however, there is no universally accepted definition of graft
failure utilized in the literature. Moreover, the lack of a
consistent approach as to the timing of when outcomes
should be measured after treatment and how such mea-
sures are reported makes appraisal of the current litera-
ture challenging, which limits the recommendations for
the patient’s best possible care.
As the body of evidence on ACL treatment grows, there is
an urgent need to reach consensus on how clinical outcome
should be assessed and reported. Surgeons and researchers
should strive to create optimal conditions for appraisal of
the cumulative evidence regarding ACL treatment,
thereby promoting an evidence-based approach by using
outcome measures that are reliable, valid, responsive over
time, and comparable. Therefore, a multidisciplinary group
of experts was assembled for an international consensus
meeting aiming to establish a standardized approach to
clinical outcome assessment for patients receiving ACL
treatment, that is, both operative and nonoperative treat-
ment.79 The purpose of this article is to provide the results
from the consensus meeting in terms of what outcomes
should be reported when conducting an ACL outcome
study, the recommended outcome measurements, and at
which follow-up time points those measurements should
be used.
METHODS
A multidisciplinary panel of national and international
experts in ACL injury, including orthopaedic surgeons,
physical medicine and rehabilitation physicians, physical
therapists, and scientists, was convened in a 1-year
consensus-building effort, which culminated in the ACL
Consensus Meeting Panther Symposium held at the
University of Pittsburgh and University of Pittsburgh
Medical Center in Pittsburgh, Pennsylvania, USA, in June
2019. The symposium included delegates from 18 countries
encompassing 6 continents. The working group of this topic
consisted of 25 participants.
A list of 13 statements on clinical outcomes was drafted by
the steering committee of the meeting based on current lit-
erature and controversies in clinical outcome assessment.
The consensus group members completed an online survey
addressing the 13 statements before the consensus meeting.
The initial statements and corresponding responses are
found in the supplementary material (Appendix).
A modified Delphi consensus discussion for each of the 13
statements was subsequently held at the in-person consen-
sus meeting. The session was moderated by 2 senior
researchers (K.E.W. and J.K.). Each statement was dis-
cussed and revised by the working group, after which a vote
on agreement with the statement was performed. No count
was held on the number of roundtables, but discussion was
continued until consensus was met for each statement. A
majority of 80% agreement was determined a priori as
being a satisfactory level of consensus. Opposing views
were documented, and it was determined that those state-
ments for which 80% agreement was not achieved should
be discussed in the paper, noting the percentage of agree-
ment and accompanied with the discussion held during the
meeting. Statements that the panel determined as irrele-
vant, redundant, or overlapping with another statement
were either excluded or combined with the overlapping
statement. Statement 2 in this consensus paper was
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combined from 2 original statements (originally statements
10 and 11 in the online survey [Appendix]) because these
were considered as overlapping. There was 100% agree-
ment for the original statement 10, and when proceeding
to discussion and voting on the original statement 11, the
panel instead agreed to combine statements 10 and 11 into
one. However, no formal voting was undertaken for the
finalized combination of the two. Thus, the percentage of
agreement for statement 2 in this consensus paper could
not be reported.
This working group was assigned 2 liaisons (E.S. and
E.H.S.), who were responsible for amending each statement
as requested over the course of the discussion. Liaisons
transcribed the discussion, performed data analyses, and
subsequently completed a MEDLINE literature review for
each finalized statement. To reduce the potential for bias in
the data analysis and/or literature review, liaisons did not
submit answers to the online questionnaire, nor did they
partake in the voting process. A description of the consen-
sus process is presented in Figure 1, and a list of definitions
used at the consensus meeting for the specific statements is
provided in Table 1.
CONSENSUS STATEMENTS AND DISCUSSION
Of the 13 statements discussed by the working group,
9 achieved consensus, and 4 were excluded because these
were considered to include information similar to 1 of the
other statements. Thus, some of the 9 statements achieving
consensus were slightly modified to include aspects from
the 4 excluded statements. The 9 final statements, with
supporting literature review, are presented below. These
statements are presented in 3 main sections for readability
purposes: (1) planning for outcome assessment, (2) clinical
outcome assessment, and (3) patient-reported outcome
(PRO). An overview of the consensus statements is pre-
sented in Table 2.
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Jon Karlsson, MD, PhD
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Andrew Lynch, PhD, PT
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Final manuscript
Clinical Outcome Consensus 
Group
Literature review of supporng 
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A nonoperatively treated ACL injury with
persistent complaints of instability more
than 6 months after initial injury.
Acute ACL
reconstruction




An ACL injury that is planned to be treated
with reconstruction and take place after 6
months from injury, or an ACL
reconstruction that takes place after
nonoperative treatment has been tried
without a satisfactory outcome.
Instability A patient’s perception of the knee not feeling
stable.
Laxity The passive displacement of the knee joint
when an external force or torque is applied.
aACL, anterior cruciate ligament.
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Section 1: Planning for Outcome Assessment
1. A priori power calculation of sample size in relation to the
primary endpoint must be performed and reported to avoid
underpowered studies (25/25; 100% agreement).
“Sample size is key to avoiding underpowered studies. We
should always try to perform high-quality research, and
power calculation is part of this.”
A critical point when evaluating a study outcome is to
ensure that the sample size is large enough to detect a
difference when a true difference in fact exists. Otherwise,
the study may be underpowered and subject to beta error
(type II error). This can have serious consequences on clin-
ical practice if no difference in outcome is concluded to exist
between, for example, 2 interventions, even though one of
the interventions is truly inferior, or superior, compared
with the other. Ultimately, underpowered studies fail to
identify the best possible care for our patients. Approxi-
mately two-thirds of randomized controlled trials related
to ACL reconstruction failed to report an a priori sample
size calculation.4,94 Although a more recent assessment of
the literature shows that these numbers have substantially
improved since 2009,54 improvements can be made. A study
should have a power of at least 80% (1 – b), which means
that the risk of a type II error, or false negative result, is
20%. A priori power calculation helps to ensure that the
sample size will be large enough to minimize the risk of
type II error. The power calculation should be determined
for the primary patient-centered endpoint, meaning that if
an endpoint is chosen that has a low event rate, the study
sample size will need to be larger than if one expects that
many patients will reach the endpoint. The sample size
calculation therefore aids in the determination of feasibility
and will help reduce the rate of incomplete studies and
wasted resources. It is also an ethical responsibility to per-
form a sample size calculation because it is unethical to
include substantially more patients than necessary. In
relation to large registry studies, a power calculation may
be redundant, but this can depend on the outcome. It is
therefore recommended that a statement on power always
should be included. A sample size calculation should be
performed whenever possible before the start of the study.
However, a post hoc power calculation to test the validity of
the study results can be an acceptable method under cer-
tain conditions, for instance, in the case of a retrospective
study, but caution must be given to the high risk of over-
estimating power.38,116
CONCLUSION. Researchers must report the power of
the study to ensure that the sample size is sufficient to
detect a difference if one truly existed and to give readers
of the paper an understanding of the strength and general-
izability of the results.
2. Improvement from pretreatment status is the outcome of
interest. Minimum description of pretreatment status
should include demographic data, validated knee-specific
PRO assessment, HRQoL, and measure of type and level of
preinjury sport/activity.
“We must know where we started to determine whether
the treatment was effective.”
The goal of all available treatments for an ACL injury is to
improve the outcome from the pretreatment status. Hence,
without assessment of the pretreatment status, the relative
improvement cannot be measured and reported. Assess-
ment of the pretreatment status is also important to iden-
tify baseline variables that may confound or explain a given
study result. When comparative trials are conducted, vari-
ables known to influence the outcome of interest should be
equally distributed between the groups or otherwise
adjusted for by using appropriate statistical methods.
Adjustments can be planned a priori based on previous
studies or assessed by adjusting for variables that correlate
with both the predictor and the outcome. Researchers
should thoroughly plan data collection before the study
start while considering their study population and their
research question.
The demographic data should give an overview of the
characteristics of the investigated population, which aids
TABLE 2
Summary of the Consensus Statements for Clinical
Outcome Assessment After ACL Injurya
Planning for outcome assessment
 A priori power calculation of sample size in relation to the
primary endpoint must be performed and reported to avoid
underpowered studies.
 Improvement from pretreatment status is the outcome of
interest. Minimum description of pretreatment status should
include demographic data, validated knee-specific PRO
assessment, HRQoL, and measure of type and level of preinjury
sport/activity.
Clinical outcome assessment
 Minimal length of follow-up when reporting outcomes depends
on the outcome being assessed and should optimally include
80% of the entire cohort.
 Comprehensive assessment after ACL surgery (minimum 2
years) should include adverse events, clinical measures of knee
function and structure, PRO, activity level, and recurrent
ligament disruption.
 Comprehensive assessment after ACL surgery in the medium
to long term (5 years) should also include measures of
posttraumatic OA.
 Clinical assessment of ACL injury treatment should include
measures of AP and rotatory knee laxity.
PRO
 Assessment of PRO should optimally include at least 1 knee-
specific outcome tool, 1 activity rating scale, and 1 measure of
HRQoL.
 The IKDC-SKF is the recommended knee-related outcome
measure for ACL injury and treatment.
 Measurement of the PASS is valuable in the assessment of
outcome of ACL injury and treatment.
aACL, anterior cruciate ligament; AP, anteroposterior; HRQoL,
health-related quality of life; IKDC-SKF, International Knee Doc-
umentation Committee Subjective Knee Form; OA, osteoarthritis;
PASS, Patient Acceptable Symptom State; PRO, patient-reported
outcome.
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to determine the generalizability of the study results.
Demographic data should at a minimum include patient
sex, age, anthropometric data, relevant medical history,
and prior knee joint injuries. Family history of ACL injuries
may also be relevant because a heritable component of ACL
injuries appears to exist.18,118 Moreover, the type and level
of preinjury sport or activity should be reported to deter-
mine whether the treatment successfully returned the
patients to their preinjury activity level. The recommended
tool for sport and activity assessment is the Marx activity
scale,66 which has been validated and has high reliability.
The Marx activity scale enables an evaluation of both the
type of activity and the exposure time, which are both crucial
aspects when reporting on activity. In this aspect, it differs
from other measures of activity, for example, the Tegner
activity scale,105 which enables grading of activity level but
does not account for activity exposure. Other validated tools
for activity include, for example, the International Knee Doc-
umentation Committee Subjective Knee Form (IKDC-
SKF),50 which includes 1 item (item 8) related to the activity
level that the patient performs on a regular basis. The item
is answered by choosing 1 of 5 responses ranging from very
strenuous activity to unable to perform light activities. Clas-
sification of activity and sports participation can also be
rated according to level I to IV activity, which was included
in the original version of the IKDC Knee Ligament Standard
Evaluation Form45 and is still frequently used in ACL
research.30,39,70 Another example of a tool for activity assess-
ment is the Cincinnati sports activity scale.9 The tools for
activity assessment are presented in Table 3. It is of impor-
tance to further distinguish between preinjury and presur-
gery activity level. Because a presurgery activity level has a
risk of being representative of the patient’s activity while
injured, preinjury activity should always be reported.
Pretreatment assessment of PROs is particularly valu-
able for patients with chronic ACL injuries or as a presur-
gical treatment baseline for patients undergoing delayed
ACL reconstruction. This is because patients with chronic
ACL injury may have had the time to live with and try to
cope with the potential limitations of their ACL-deficient
status as opposed to the acutely injured patients who are
impaired because of injury-related factors (eg, pain and
hemarthrosis). There is, however, no strict definition for
what should be regarded as early and delayed ACL recon-
struction, and the timing of ACL reconstruction varies con-
siderably between geographical regions.87 Surgery within 3
weeks has been defined as an early ACL reconstruc-
tion,33,101 although this definition is not consistent, and a
recent literature review found that the definition of early
ACL reconstruction ranged from 2 days to 7 months among
the included trials.2 For correct interpretation of the pre-
treatment assessment, it is important that the time from
injury to pretreatment assessment is always reported, as
outcomes may be very different for a patient who is com-
pleting such an assessment soon after injury compared
with a patient who was injured many years previously.
The impact of the ACL injury on the patient’s overall well-
being and quality of life before treatment should also be
measured.72,85 A health-related quality of life (HRQoL)
measure covers a larger picture of how an ACL injury affects
a patient in terms of physical, social, and emotional health,
which must not be overlooked among patients sustaining an
ACL injury.34 Pretreatment assessment of HRQoL allows for
evaluation of health status over time and whether the treat-
ment restores the patient to better, similar, or worse health.
Most measures of HRQoL also have the advantage of provid-
ing the possibility to determine utilities that are used in
estimating the economic impact of the injury and allow for
comparison between many other conditions and treatments.
A list of HRQoL measures is provided in Table 4.
CONCLUSION. Description of the sample in terms of
demographic characteristics, preinjury activity level, and
pretreatment PROs is necessary to interpret the results of
treatment and generalizability of the study.
Section 2: Clinical Outcome Assessment
3. Minimal length of follow-up when reporting outcomes
depends on the outcome being assessed and should
optimally include 80% of the entire cohort (25/25; 100%
agreement).
“An 80% follow-up rate is optimal. Follow-up time
should reflect the primary outcome, be based upon the
purpose of the study, and be stated a priori.”
The follow-up time of a study should be defined depending
on what is relevant in relation to the primary investigated
outcome. In general, outcomes after ACL treatment can be
divided into 4 categories: early adverse events, PROs, ACL
failure/recurrent ligament disruption, and clinical mea-
sures of knee function and structure (Table 5), all of which
could be further stratified in specific outcomes, necessitat-
ing different considerations for follow-up time as exempli-
fied in Table 6.
Evidence provided by previous research as well as clinical
experience is the foundation to determine what a relevant
follow-up time is. For example, the rates of ACL rerupture
and ACL revision peak at 1 to 2 years after an ACL recon-
struction and with return to sport (RTS).32,40,61,82,118 There-
fore, a study with a shorter follow-up than this is not
relevant if the primary outcome is rerupture or ACL revi-
sion, and a study aiming to make conclusions about ACL
treatment failure should not have a follow-up time of less
than 2 years and should report RTS as a proxy of risk expo-
sure. In contrast, the outcome of septic arthritis or hardware
failure can manifest soon after an ACL reconstruction,99,114
and a follow-up time of6 months is sufficient to collect data
that will represent a true estimation of such outcomes. Thus,
it is important that the follow-up time is defined and based
upon the study aims and outcomes.
In most studies, especially with increasing length of
follow-up time, a certain degree of patients lost to follow-
up is inevitable. Even a small proportion of patients lost to
follow-up can lead to considerable study bias,16 although a
common opinion is that a dropout rate of more than 20% is
associated with a serious threat to the internal and external
validity and power of the study.93 A study is therefore recom-
mended to optimally include at least an 80% follow-up rate.
However, the possibility of dropout/retention bias should
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always be considered when patients are lost to follow-up.
Data should be presented such that the dropout rate is accu-
rately reported. A strict adherence to the use of checklists is
encouraged to facilitate complete data reporting, such as the
CONSORT (Consolidated Standards of Reporting Trials)
statement97 for randomized controlled trials and the
STROBE (STrengthening the Reporting of OBservational
studies in Epidemiology) statement113 for cohort studies.
Clear step-by-step flowcharts are encouraged. Whenever
dropouts are present, the authors are recommended to per-
form a dropout sensitivity analysis to enable interpretation
of the possible dropout effects. This should include a compar-
ison of the baseline characteristics of those who completed
versus those who did not complete the study.
TABLE 3
Tools for Activity Assessmenta
Assessment Tool Description
IKDC-SKF50 4: Very strenuous activities like jumping or pivoting as in basketball or soccer
3: Strenuous activities like heavy physical work, skiing, or tennis
2: Moderate activities like moderate physical work, running, or jogging
1: Light activities like walking, housework, or yard work
0: Unable to perform any of the above activities because of knee
Tegner activity scale105 Level 10 competitive sports: soccer, football, rugby (national elite)
Level 9 competitive sports: soccer, football, rugby (lower divisions), ice hockey, wrestling, gymnastics,
basketball
Level 8 competitive sports: racquetball or bandy, squash or badminton, track and field athletics
(jumping, etc), downhill skiing
Level 7 competitive sports: tennis, running, motorcar speedway, handball;
recreational sports: soccer, football, rugby, bandy, ice hockey, basketball, squash, racquetball,
running
Level 6 recreational sports: tennis and badminton, handball, racquetball, downhill skiing, jogging at
least 5 times per week
Level 5 work: heavy labor (construction, etc);
competitive sports: cycling, cross-country skiing;
recreational sports: jogging on uneven ground at least twice weekly
Level 4 work: moderately heavy labor (eg, truck driving, etc)
Level 3 work: light labor (nursing, etc)
Level 2 work: light labor;
recreational sports: walking on uneven ground possible but impossible to backpack or hike
Level 1 work: sedentary (secretarial, etc)
Level 0: sick leave or disability pension because of knee problems
Marx activity scale66 Patient is asked how often the activities running, cutting, deceleration, and pivoting have been
performed during the last year in his/her healthiest and most active state. Each activity is scored on
a 0-4 scale as follows:
0: <1 time in a month
1: 1 time in a month
2: 1 time in a week
3: 2-3 times in a week
4: 4 times in a week
Cincinnati sports activity scale9 Divided into 4 major levels with subcategories
Level I: participates 4-7 d/wk
Level II: participates 1-3 d/wk
Level III: participates 1-3 times/mo
Level IV: no sports
Subcategories for level I-III (5-point decline for every step downward, starting from 100 points):
Jumping, hard pivoting, cutting (basketball, volleyball, football, gymnastics, soccer)
Running, twisting, turning (tennis, racquetball, handball, ice hockey, field hockey, skiing,
wrestling)
No running, twisting, jumping (cycling, swimming)
Level IV with the following subcategories and points for each:
40: Activities of daily living without problems
20: Moderate problems with activities of daily living
0: Severe problems with activities of daily living, on crutches, full disability
IKDC Knee Ligament Standard
Evaluation Form45
Level I: jumping, pivoting, hard cutting, football, soccer
Level II: heavy manual work, skiing, tennis
Level III: light manual work, jogging, running
Level IV: activities of daily living, sedentary work
aIKDC-SKF, International Knee Documentation Committee Subjective Knee Form.
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It should be emphasized that there can be circumstances
where an acceptable follow-up rate for a study is deter-
mined by weighing the disadvantages of loss to follow-up
against certain advantages, for example, a long-term
follow-up or a considerable amount of data in a study. In
such cases, a lower threshold for follow-up rate is accept-
able. Large registry studies can be used to exemplify this,
where the patient response rates to PROs are a challenge.43
Registries comprise data on large numbers of patients and
include multiple follow-up occasions, sometimes over more
than a decade.43,103 Hence, they are important sources for
determining the effectiveness of ACL treatment and for
providing hypotheses-generating results.104 Nonetheless,
a large dropout rate increases the importance of a stringent
data reporting, and a statistical analysis of patients lost to
follow-up also needs to be considered.
CONCLUSION. Follow-up time should be determined by
the purpose of the study and primary outcome and should be
stated a priori. The follow-up rate should optimally exceed
80%, and data must be reported so that the possible effects
of patients lost to follow-up can be considered.
4. Comprehensive assessment after ACL surgery (minimum
2 years) should include adverse events, clinical measures
of knee function and structure, PRO, activity level, and
recurrent ligament disruption (25/25; 100% agreement).
“The comprehensive assessment needs to cover both clin-
ical assessment and the patient’s perspective and should
optimally also include RTS.”
A comprehensive assessment after ACL reconstruction
should aim to provide a complete picture of outcome related
to different dimensions of limitations, which involves
numerous aspects of knee-related health and function,
objective assessment of hard endpoints (Table 6), and tech-
nical aspects of the surgery (graft choice, fixation, tunnel
placement, meniscus/cartilage assessment, and treatment).
A minimum follow-up of 2 years is likely necessary to
enable a comprehensive assessment. Multiple follow-ups
during the first 2 years could certainly fulfill the purpose
of evaluating, for example, the progress such as in the
early, middle, and end state of the rehabilitation. However,
the final assessment should be withheld until 2 years post-
operatively because a substantial number of outcomes
require that this time has been given for the ACL recon-
struction to completely heal47,83,112,123 and for the patient
to complete rehabilitation and progress to testing the knee
in more demanding activities including full participation in
sport or activity. A follow-up of 2 years should allow for
determining the patient’s capability of a successful RTS,6
and importantly, it will include a period when patients are
participating at high-risk exposure for ACL failures and
reinjuries.32,40,61,82,118 An optimal 2-year outcome assess-
ment should therefore include reporting of the rate and time
of RTS. A consensus statement related to assessment and
reporting of RTS was similarly reached at the ACL Consen-
sus Meeting Panther Symposium 2019 and is provided in a
separate publication.67
A comprehensive assessment also implies that the con-
tralateral knee should be examined and assessed for each
outcome. Outcome tools such as the IKDC Knee Ligament
Standard Evaluation Form45 require a comparison with the
contralateral knee for the standardized reporting. The unin-
jured contralateral knee serves as a reference for the
ACL-injured knee in terms of range of motion, laxity, and
functional performance,119 which helps to account for differ-
ences between patients. It should also be noted that the con-
tralateral limb/leg/knee might also be affected by an ACL
injury such as altered kinematics53,68 and a decrease in mus-
cle strength,119 which underscores the importance to ensure
that the function of the contralateral limb is optimized before
allowing the patient to return to knee-strenuous activities by
assessing it likewise. It is therefore recommended that the
standard practice is to assess the contralateral knee and
report such data, which ultimately will contribute to
increased knowledge of risk factors for a patient sustaining
a subsequent contralateral ACL injury.
TABLE 4
Health-Related Quality of Life Outcome Measuresa
Instrument Developer No. of Items Response Options
KOOS Roos et al91 42 items, of which 5 are related to quality of life Each item scored 0-4
ACL-QoL Mohtadi69 32 items A 100-mm visual analog scale for each item
SF-817 Quality Metric 8 items Each item scored on a 6-point scale
EQ-5D31 EuroQoL 6 items Item specific
SF-36 Ware and Sherbourne115 36 items Item specific
SIP Bergner et al15 136 items Yes/no
QWB Anderson et al3 71 items Via interview
aACL-QoL, Quality of Life Outcome Measure for Chronic Anterior Cruciate Ligament Deficiency; EQ-5D, European Quality of Life–5
Dimensions; KOOS, Knee injury and Osteoarthritis Outcome Score; QWB, Quality of Well-Being; SF-8/SF-36, Short Form Health Survey;
SIP, Sickness Impact Profile.
TABLE 5
4 Robust Outcome Categories After ACL Injury Treatmenta
Adverse events
PRO measurements
ACL failure or recurrent ligament disruption
Clinical measures of knee function and structure
aACL, anterior cruciate ligament; PRO, patient-reported out-
come.
The Orthopaedic Journal of Sports Medicine Clinical Outcomes After ACL Injury 7
Failure of ACL reconstruction is a nonspecific term
that is commonly used without a stringent definition in
the literature. It is therefore recommended that well-
defined outcome assessments are used and that the
authors, if choosing to use the term failure, report an
a priori definition of what a failure is in detail. To
define failure as reoperation is verifiable and clear;
however, it introduces a risk of underestimating the
true failure rate. Other examples of definitions for ACL
graft failure include recurrent/persistent instability,
pathological anterior or rotatory laxity, or evidence of
graft failure assessed by magnetic resonance imaging
(MRI) or arthroscopic surgery. In overall terms, reasons
for ACL failure may be classified as traumatic (eg, rein-
jury), technical (eg, surgical errors), and patient related
(eg, compliance to rehabilitation, recovery of neuromuscu-
lar function, or generalized hyperlaxity). Technical errors
account for a great amount of all graft failures, with fem-
oral tunnel malposition being a common cause.71,106 It has
also been reported that previous tibial tunnel malposition
is a significant predictor for worse 2-year PROs after ACL
revision.122 It is therefore recommended that reporting of
ACL reconstruction failure is complemented by reporting
of details with regard to the surgical technique. A useful
tool is the Anatomic ACL Reconstruction Scoring
Checklist (AARSC),107 which enables grading of surgical
variables that define ACL tunnel position in an anatomic
manner.
CONCLUSION. A minimum of 2-year follow-up is nec-
essary for a comprehensive and reliable determination of
outcome. The comprehensive assessment should include
outcomes provided by clinical examination, PROs, activity
level, and verified reinjuries.
5. Comprehensive assessment after ACL surgery in the
medium to long term (5 years) should also include
measures of posttraumatic OA (25/25; 100% agreement).
“A common methodology of outcome assessment for OA is
needed and should be included in midterm to long-term
follow-up studies.”
It is well known that sustaining an ACL injury entails a
high risk of developing posttraumatic OA in the midterm to
long term, especially if concomitant intra-articular injuries
are present.1,21,81,86 Reducing the risk of OA is a clinical
priority, which means that the midterm to long-term
follow-up assessment should include measures of OA to mon-
itor and evaluate the degenerative changes in the knee joint.
This is necessary for developing therapeutic interventions
aiming to counter the high rate of OA after an ACL injury.
Measures of OA may include clinical examination,
PROs, and imaging modalities. Clinical examination find-
ings that may indicate OA are joint-line tenderness or
crepitus, which previously have been found to be strong
predictors for OA.96 Good interobserver reliability for
TABLE 6
Examples of Outcome Measurements and Considerations for Follow-up Timea
Outcome Category Example of Specific Outcome Comment
Adverse events Intraoperative complications Usually less than 1-year follow-up required to detect these outcomes.
When identifying adverse events, these should be reported as soon as
possible, regardless of the minimum time lapsed from treatment
start.




PRO Validated knee-specific outcome scores Depending on study purpose, population, and the specific outcome tool
used. Generally, at least 1-year follow-up is required to obtain
meaningful measures for interpretation of treatment effect,
preferably 2 years. However, for the IKDC-SKF and the KOOS, the 1-
and 2-year results have been reported equivalent.80,95 Patients could
be followed over several years to detect changes over time and to








Graft rupture/failure The follow-up time must allow for sufficient time to detect events such
as rerupture and ACL revision. These events tend to occur after the
patient returns to knee-strenuous activities, which means that a 2-






Strength testing Largely depending on the specific outcome and the study purpose.
However, care should be taken not to draw conclusion about the
short-term treatment result until a 2-year follow-up is obtained.
Functional performance tests, knee joint laxity, and range of motion
assessments are preferably performed in multiple follow-ups before
the 2-year follow-up for changes over time. OA assessment should
have at least 5-year follow-up. Concomitant knee joint injuries should







Concomitant knee joint injuries
aACL, anterior cruciate ligament; HRQoL, health-related quality of life; IKDC-SKF, International Knee Documentation Committee
Subjective Knee Form; KOOS, Knee injury and Osteoarthritis Outcome Score; OA, osteoarthritis; PRO, patient-reported outcome; RTS,
return to sport.
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joint-line tenderness and crepitus has been reported when
a standardized approach is used.65 The IKDC Knee Liga-
ment Standard Evaluation Form includes a grading sys-
tem for such an examination and should be used for
standardized reporting.45
The use of PROs is valuable to capture the patients’ per-
ception of impairments caused by OA. Questionnaires spe-
cifically developed and validated for assessment of OA are
the Western Ontario and McMaster Universities Osteoar-
thritis Index (WOMAC)13 and the Knee injury and Osteo-
arthritis Outcome Score (KOOS).91 However, the WOMAC
was developed for evaluation of established OA; as such,
the KOOS may be a more appropriate assessment for
patients after ACL injury. This is because the KOOS is
more likely to detect early development of OA compared
with WOMAC, as the KOOS was developed to cover a
broader spectrum from knee injury to manifest OA.91,92
Imaging modalities still provide the most sensitive assess-
ment of OA, although not without limitations. One should
remember that radiographic findings of OA are not necessar-
ily accompanied by symptomatic OA,5,84 and other intra-
articular abnormalities may give similar symptoms as OA.
It is therefore recommended to combine radiographic imaging
assessment with PROs for decision making when it comes to
symptomatic OA. Radiographic findings should be described
in a standardized manner using validated tools, where the
Kellgren-Lawrence perhaps is the most commonly used tool,
taking into account osteophyte formation, sclerosis, joint
space narrowing, and bone deformity.55 Although plain radi-
ography has long been the established method for imaging of
OA, it must be acknowledged that the modality has a limited
capacity to visualize early stages of OA and to grade OA
progression.63
The rapid evolution of MRI techniques enables a much
more comprehensive assessment of knee joint structure,
such as early morphological and biochemical changes of
articular and periarticular structures. Quantitative mea-
surements of cartilage thickness on MRI have a higher sen-
sitivity for knee OA compared with traditional radiological
measures.121 In addition, MRI detects characteristic OA
signs earlier and with a greater sensitivity compared with
radiography.41 Structural intra-articular changes are
indicative for OA and can be seen as early as 2 years after
an ACL reconstruction with MRI, which is earlier than
these changes can be seen on radiographs.19,108 In addition,
MRI can also rule out other intra-articular injuries that
may explain symptoms perceived by patients. Thus,
although plain radiography has an established role in
assessment of OA and is favorable from an availability and
cost perspective, its main role is to assess the development
of OA in the long term and for already established OA. For
early or midterm assessment of OA, attempts should be
made to include MRI to detect early changes with greater
validity and sensitivity.41
It is not known when clinically relevant posttraumatic OA
occurs or when in this process the structural changes of the
knee joint start to appear. With advancement in imaging
techniques, there is a risk of overdiagnosis of OA because
structural changes without clinical significance might be
detected. Future research will hopefully provide a clearer
picture of this as well as methods todistinguishbetween what
are pathological changes and what changes are related to
normal aging.64 Until then, an assessment of knee OA should
always be made in relation to a “control knee” to provide a
reference for such variables. A synthesis of current literature
shows that the contralateral knee is most commonly used for
this purpose, followed by using an age- and sex-matched con-
trol group.86 The latter methodology, using a separate com-
parison group, is the preferred method because degeneration
can occur inthe contralateral knee,although itwas not partof
the original injury. Some studies have used baseline imaging
of the acute ACL-injured knee as the control,1 which cannot
be recommended because this method does not take into
account the impact of natural aging occurring between the
injury and the long-term follow-up.
CONCLUSION. Outcome assessment of OA should
include clinical examination, PROs, and imaging modalities,
for which MRI is the preferred modality for increased accu-
racy. Imaging findings should always be set in context with
the patient’s perception and the clinical examination for
decision making. Hence, these outcome assessments are
equally important for determining the outcome of OA.
6. Clinical assessment of ACL injury treatment should include
measures of anteroposterior and rotatory knee laxity (25/25;
100% agreement).
“Evaluation of knee joint laxity is a cornerstone for eval-
uating the outcome of ACL treatment. Quantitative mea-
sures of knee joint laxity increase the reliability and
validity.”
The anatomic properties of the ACL make it a primary pas-
sive restraint to both anteroposterior (AP) and rotatory
forces of the knee joint.46 Valid assessment of knee joint
laxity is therefore key in the evaluation of the outcome of
surgical treatment after ACL injury, preferably at multiple
follow-ups to detect any changes over time. Failure to elim-
inate knee joint laxity with ACL reconstruction could indi-
cate treatment failure, while patients undergoing
nonoperative treatment should be assessed for excessive
laxity or propagation of knee joint laxity. The latter sce-
nario might be an indication for subsequent operative treat-
ment, although the term laxity should be distinguished
from instability or stability. Knee joint laxity is defined as
the passive response of the knee joint when an external
force or torque is applied, while instability is the patient’s
perception of symptoms during functional movement inde-
pendent of laxity.78 Hence, knee joint laxity can be reliably
measured and reported, which makes it the preferred met-
ric for clinical outcome assessment. To minimize the risk of
bias, every attempt should be made to blind the assessors,
and all participating assessors should be trained in using a
standardized execution technique of the laxity test.
Laxity assessment consists of static and dynamic examina-
tions, and methods for both grading by the examiner and
quantification of laxity have been developed. Laxity assess-
ments should always include a side-to-side comparison with
the contralateral knee. Static AP knee laxity tests consider a
single degree of freedom of motion and include application of a
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unidirectional force in a single plane, such as the Lachman
test and the anterior drawer test. The IKDC Knee Ligament
Standard Evaluation Form provides a standardized classifi-
cation of the degree of AP translation.45 For instrumented
quantitative assessment of AP laxity, the KT-1000/2000 arth-
rometer (MEDmetric Corp)27 and the Rolimeter (Aircast)8
provide among the most accurate measurements, although
the intraclass correlation coefficient is variable according to
the literature, and the results are examiner dependent.88
Another instrument is the GNRB (Genourob), which is a
robotic arthrometer developed toalleviate the difficulties with
examiner-dependent measurements. The patient’s leg is
placed in the robotic system, and a predefined force
is applied to the proximal calf, while the relative displacement
of the anterior tibial tubercle with respect to the patella is
recorded by a displacement sensor. The GNRB also offers the
advantage of using electromyography sensors to record ham-
string activity to detect incomplete hamstring relaxation that
affects the result.89 Static AP measurements do not necessar-
ily correlate with clinical outcome and function,7,57,58 which
indicates that laxity assessment should not solely rely on
static AP translation because it fails to capture the more com-
plex knee kinematics.
The pivot-shift (PS) test is considered to simulate a more
physiological multiaxial loading of the knee joint because it is
a dynamic test of laxity that evaluates both AP and rotatory
laxity.48 It has been reported as the most specific test for ACL
deficiency.14 On the other hand, the PS is characterized by a
large variability in execution techniques,60,77 which may lead
to a variation in clinical grading between examiners. To over-
come this, a standardized PS test has been described, which
has led to an improved accuracy of the test.77 Moreover, user-
friendly devices for noninvasive quantitative PS have been
developed and determined to be valid for objective assess-
ment of the PS.76 Such devices may include an inertial sensor
system (KiRA; Orthokey)124,125 to quantify the tibial acceler-
ation during the PS and an image analysis system,74 which
enables a quantification of the lateral tibial translation dur-
ing the PS. Both devices have been shown be able to validly
detect differences between clinically high- and low-grade PS
(Figures 2 and 3).76 Examples of devices for quantitative AP
and rotatory knee laxity that are easily applicable in the clin-
ical setting are summarized in Table 7.
CONCLUSION. Knee joint laxity should be assessed after
ACL treatment and reported in a standardized manner using
the IKDC Knee Ligament Standard Evaluation Form when
clinical grading is used. The use of quantitative measures is
encouraged to increase the reliability and validity of the
assessment.
Section 3: Patient-Reported Outcome
7. Assessment of PRO should optimally include at least 1
knee-specific outcome tool, 1 activity rating scale, and
1 measure of HRQoL (25/25; 100% agreement).
“There is a fine balance between multiple outcome assess-
ments and the responder burden in clinical outcome
assessment.”
The use of PROs has become a cornerstone for researchers to
understand the patients’ perspective of the impact of ACL
injury and treatment. During recent decades, technical
development has facilitated the use of PROs, as patients can
report and researchers can collect responses electronically.
The time-efficient collection has tempted researchers to bur-
den patients with more PROs in studies. Responder burden
is an important term in research and is defined as the time to
complete items as well as the physical energy and cognitive
demands placed on those responding. In addition, all clinical
testing of patients is part of the burden placed on our
patients. Because of the risk of excessive responder burden,
which threatens the validity of a patient’s responses and
thus their score, researchers are advised to wisely choose
PROs specific for the study purpose.
Similar to statement number 2 of this consensus paper on
baseline information to collect, it is recommended to use at
least 1 knee-specific tool, 1 HRQoL tool, and 1 activity rating
scale. This provides the researcher with a comprehensive pic-
ture of the patients’ perception of outcome after treatment.
CONCLUSION. To give a comprehensive assessment of
the patients’ perception of the impact of ACL injury and
outcome of treatment, validated knee-specific PRO assess-
ment, HRQoL, and measure of type and level of preinjury
Figure 2. The KiRA inertial sensor system for quantifying lat-
eral tibial acceleration during the pivot-shift test.
Figure 3. Image analysis system on iPad for quantifying lat-
eral tibial translation during the pivot-shift test.
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sport/activity should be collected before and after
treatment.
8. The IKDC-SKF is the recommended knee-related outcome
measure for ACL injury and treatment (24/25; 96%
agreement).
“It is important to find a universal metric. The IKDC-
SKF is currently the optimal scale, but we should be
careful not to neglect the other scores.”
The evaluation of treatment outcome started historically
with use of objective measurements as proxies for what
clinicians and patients really cared about. For instance,
both rating scales and measures of range of motion,
strength, and laxity were frequently used; however, these
measures are limited by interrater and intrarater variabil-
ity and alone failed to determine symptoms and limitations
perceived important by the patient. Failure to report and
quantify the patients’ perspective of treatment outcome
after ACL injury led to the development of knee-related
PROs during the late 1990s and early 2000s. The 2 most
commonly used PROs after ACL injury are the KOOS and
the IKDC-SKF, which were both developed during this time
period. Measurement properties of the IKDC-SKF and
KOOS are presented in Table 8.
These PROs have advantages and disadvantages, and
when choosing between them, one should evaluate what the
population is and what it is that you want to capture. Most
importantly, measurements should consist of those that are
relevant to the patient and capture the full range of symp-
toms, activity limitations, and participation restrictions
to increase the relevance and validity in results attained
from PROs.23 It is essential that the PROs have undergone
rigorous validation to the target condition to be able to
differentiate better from worse treatment outcome. The
inappropriate use of a PRO can distort results from a study
and cause difficulties to detect differences, as items may not
be relevant for the given population. This can be the case
when a questionnaire aimed to assess outcome in patients
with OA is used to assess patients with an ACL injury.
The KOOS is an extension of the WOMAC12 (covers the
subscales of Pain, Symptoms, and limitations in Activities of
Daily Living) and was validated for patients with OA of the
knee. The initial idea of the KOOS was to develop a region-
specific outcome to capture the progression of knee-related
symptoms across the life span of a patient from knee injury
to the development of OA. Despite the inclusion of the Sport
and Recreation and Quality of Life subscales, the KOOS has
TABLE 7
Devices for Quantitative Assessment of Knee Joint Laxitya
Device Accuracy Comment
KT-1000/2000 arthrometer The majority of studies show at least a fair
reproducibility (intertester ICC range, 0.14-0.92;
intratester ICC range, 0.47-0.95).88
Measure anterior tibial displacement in millimeters.
Different reliability depending on examiner
experience.88 Dependent on dominant hand of the
examiner.100 The maximal manual force testing is
the most reliable.88
Rolimeter The literature shows an intertester correlation ranging
between 0.39 and 0.89 and intratester correlation
ranging between 0.55 and 1.00.73,98
Measure anterior tibial displacement in millimeters.
Not as crucial with examiner experience compared
with the KT-1000 arthrometer.73 Might be easier to
apply in the clinical setting compared with the KT-
1000 arthrometer because of the lighter design. At
least as reliable as the KT-1000 arthrometer.88
GNRB Sensitivity and specificity for an ACL tear ranging
between 62% to 92% and 76% to 99%,
respectively.11,56,89 The intertester ICC has been
reported ranging between 0.220 and 0.424.110
Measure anterior tibial displacement in millimeters.
Robotic testing meaning a less examiner-dependent
measurement. Several studies reporting the GNRB
as reliable as or superior to other arthrometers.90
Possible to account for patient guarding with
hamstring activation.89
Pivot App Excellent intertester and intratester reliability
reported. Intertester ICC of 0.95 (95% CI, 0.54-1.00)
and intratester ICC ranging between 0.91 and 0.99
(95% CI, 0.319-1.000).74
Lateral tibial translation during the PS test is
calculated (in mm) by a software program analyzing
the movement of 3 markers placed on the skin during
video recording of the PS test using a commercial
tablet. Been proved valid to detect differences
between clinically high- and low-grade PS.76
KiRA Mean intrarater ICC of 0.79. Reproducibility is good to
excellent across all different parameters being
quantified (minimum, maximum, and range of tibial
acceleration).62
An inertial sensor system quantifies the tibial
acceleration (m/s2) during the PS test. An elastic
strap is used to position the sensor on the patient’s
leg when executing the PS test. Has been proved to
be valid to detect differences between clinically high-
and low-grade PS.76
aACL, anterior cruciate ligament; ICC, intraclass correlation coefficient; PS, pivot shift.
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limited measurement properties in the 3 original WOMAC
subscales when used for patients after ACL reconstruc-
tion.23,59 It is also worth mentioning that the hybrid version
of the KOOS, the KOOS4 (a modified version in which the
items related to activities of daily living have been excluded
to avoid ceiling effects)36 has not undergone a valida-
tion.22,23 This is problematic, as the ability to detect differ-
ences between treatments will be limited with the KOOS
used in patients with an ACL injury.59 Using PRO measure-
ments that include items that are not relevant or do not
cover important limitations of the target condition is not
optimal. Using such PROs entails a potential washout of
treatment effects, inadequate measurement properties, and
risk of false negative findings.23,95,102 In terms of the KOOS,
several questions are at risk for a ceiling effect when used in
patients after ACL reconstruction; that is, the item is too
“easy” for the patient. In addition, the KOOS does not
include specific items relating to instability, which is one
of the most common symptoms and one of the strongest
indications for an ACL reconstruction. The KOOS consists
of 42 items entailing higher responder burden compared
with other outcomes such as the IKDC-SKF. Awareness of
the limitations of the KOOS for the patients after an ACL
injury or reconstruction is important to avoid missing the
effects of treatment results.
The IKDC-SKF was developed as a region-specific out-
come relevant for a variety of conditions including ligament
and intra-articular abnormalities.50 This PRO underwent
rigorous testing during its development including a reduc-
tion from 42 to 18 items and an exploratory factor analysis,
suggesting that it was reasonable to combine the items into
a single overall score. To test the relevance of the IKDC-
SKF for patients with an ACL injury, Rasch analysis was
performed separately for patients with and without knee
ligament injury.50,109 The analysis supported the premise
that the items of the IKDC performed similarly in terms of
difficulty for individuals with or without a ligament injury.
The results from the primary testing of the IKDC-SKF also
indicated that the IKDC-SKF items performed the same,
regardless of age, sex, and a variety of diagnoses including
ligament, meniscal, and articular cartilage injury and
patellofemoral pain.29,50
The IKDC-SKF is recommended as the knee-related
PRO to use for patients after ACL reconstruction because
of its quick-to-use 18 items.50 The IKDC-SKF shows ade-
quate internal consistency and has no floor or ceiling effects
across mixed groups of patients with knee conditions.29 It
also has high levels of test-retest reliability, construct
validity, and responsiveness. Moreover, normative data
have been determined, which is valuable for comparisons
as well as cutoffs for what the patients consider an accept-
able symptom state.52
There are also other promising PROs used to cover dif-
ferent aspects of recovery after ACL reconstruction, includ-
ing the Quality of Life Outcome Measure for Chronic
Anterior Cruciate Ligament Deficiency (ACL-QoL)69 and
the Knee Numeric-Entity Evaluation Score (KNEES-
ACL).24 The ACL-QoL is used to determine the effective-
ness of ACL reconstruction, or any other treatment, and is a
32-item condition-specific quality of life scale for patients
with ACL deficiency.69 The KNEES-ACL was developed in
2013,24 and the thorough development process and dimen-
sionality assessment resulted in 42 items across 7 latent
constructs. There is strong positive evidence given to con-
tent validity.24,25
The ACL-QoL and the KNEES-ACL are promising out-
come measurements and likely will help us to better under-
stand patients who have sustained an ACL injury. However,
these PROs have mainly been used in comparative studies
and are yet to be compared with the established IKDC-SKF
and KOOS to prove their respective strengths of constructs.
CONCLUSION. The IKDC-SKF is the recommended
knee-related outcome measure for ACL injury and
treatment.
TABLE 8
Psychometric Properties of the IKDC-SKF and the
KOOS37a
IKDC-SKF KOOS











MDC 11.5 Pain ¼ 6.0 to 6.1
Symptoms ¼ 5.0 to 8.5
ADL ¼ 7.0 to 8.0
Sport ¼ 5.8 to 12.0
QoL ¼ 7.0 to 7.2
Content validity Poor No evidence
Structural validity No evidence No evidence
Internal consistency 0.77 to 0.97 Pain ¼ 0.84 to 0.91
Symptoms ¼ 0.25 to 0.75
ADL ¼ 0.94 to 0.96
Sport ¼ 0.85 to 0.89
QoL ¼ 0.64 to 0.90
Measurement error 3.2 to 5.6 Pain ¼ 2.2 to 10.1
Symptoms ¼ 3.1 to 9.0
ADL ¼ 2.9 to 11.7
Sport ¼ 2.1 to 24.6
QoL ¼ 2.6 to 10.8
Test-retest reliability 0.85 to 0.99 Pain ¼ 0.85 to 0.93
Symptoms ¼ 0.83 to 0.95
ADL ¼ 0.75 to 0.91
Sport ¼ 0.61 to 0.89
QoL ¼ 0.83 to 0.95
Responsiveness Good Poor
Cross-cultural validity Fair No evidence
aADL, Activities of Daily Living; IKDC-SKF, International
Knee Documentation Committee Subjective Knee Form; KOOS,
Knee injury and Osteoarthritis Outcome Score; MCID, minimal
clinically important difference; MDC, minimum detectable change;
MIC, minimally important change; N/A, not available; PASS,
Patient Acceptable Symptom State; QoL, Quality of Life.
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9. Measurement of the patient acceptable symptom state
(PASS) is valuable in the assessment of outcome of ACL
injury and treatment (25/25; 100% agreement).
“One question can carry the advantage of giving the
patient the opportunity to tell the story.”
As researchers and clinicians of today, we are equipped
with a great variety of PROs. However, the development
and use of these PROs means little if the results are not
interpreted in a clinically meaningful manner. The use of
numeric scores poses a risk that researchers focus myopi-
cally at numbers and statistically significant findings with-
out reflecting over whether such findings really are
impactful from the patient’s perspective. For many such
PROs, the same score can be achieved, despite that patients
respond differently to the items that comprise the PRO
measure. The question of whether the patient perceives
an acceptable symptom state is a priority for all clinicians,
and the use of the PASS in PRO assessment is important.
The PASS considers a single-item question and aims to
determine a threshold beyond which the patients consider
themselves “well.”75 Thresholds for the PASS have been
established for the KOOS and the IKDC-SKF by asking the
question “Taking account of all the activity you have during
your daily life, your level of pain, and also your activity
limitations and participation restrictions, do you consider
the current state of your knee satisfactory?” alongside the
administered PRO.75 Several studies have since then
applied the PASS values for the KOOS and IKDC-SKF
when reporting on outcome after ACL treatment.26,42,44,111
A single-item outcome like the PASS summarizes the
patient’s perception and allows the patient to make an over-
all statement through a binary answer: “yes” or “no.” A
numeric scale might have its advantages; however, it is
associated with difficulties of interpretation for both
patients and researchers. That is, what is considered as a
good and poor outcome, respectively? The PASS reference
value at which a majority of the patients feel well is valu-
able for determining this important question, and its use is
warranted to overcome limitations with numeric PROs
such as ceiling effects and poor responsiveness.49,72
In addition, the evidence to support the interpretation
and use of a PRO should include the minimum detectable
change (MDC) score and the minimal clinically important
difference (MCID) score. These scores collectively describe
the responsiveness of the PRO, which is the ability to detect
a clinically important change in outcome for the metric. The
MDC is the amount of change that is needed to confidently
state that the change is beyond measurement error.10
Thus, if a study finds a difference that is smaller than the
MDC for the chosen PRO, one should be careful to draw any
conclusions because the observed difference is within the
range of measurement error for the PRO. On the other
hand, if the change in outcome is larger than the MDC, it
still remains unknown whether this change is clinically
relevant. This is where the MCID becomes valuable. If a
change in outcome exceeds the value of the MCID for the
PRO, the difference is likely to be perceived as important by
most patients.51
CONCLUSION. The PASS is a valuable complement to
numeric PROs and should be used to facilitate interpreta-
tion of PROs. Researchers should also consider the MDC
and MCID for the PRO when reporting and discussing their
study findings.
FUTURE DIRECTIONS
Reaching consensus for clinical outcome assessment after
ACL treatment is an important step toward refining and
improving the quality of ACL research. Further efforts
should be made to develop methods for outcome assessment
that provide the most relevant and valid data for patients
receiving ACL treatment. A focus is to improve the PRO
assessment. The collection of PROs has become increas-
ingly important among health care professions. Not only
is it a valuable asset for a clinician to understand a patient’s
perception of health and results of treatment, it has also
gained importance for policy makers in determining health
care quality and developing a value-based health care.72
Commonly used PROs in ACL research are limited by a
format of fixed-length surveys that many times include
items of questionable relevance for the young and active
population sustaining ACL injuries, leading to ceiling
effects and potentially survey fatigue. Therefore, a current
priority is to decrease the responder burden for patients in
PRO assessment.
Improved PRO data collection may be achieved through
the use of the item response theory (IRT),20,35 which has
enabled the introduction of computer adaptive testing
(CAT). The underlying premise of IRT is that the way a
patient responds to an item (question) is based on the dif-
ficulty of the question and the ability of the patient. When
administered as a CAT, a mathematical algorithm is uti-
lized to select items that are matched to the ability of the
patient. For example, if a patient responds to an item that
he/she is unable to walk a mile, the computer algorithm will
bypass “harder” items such as running a mile and select an
easier item such as ability to walk a block. This means that
only items that are relevant about the patient’s ability level
are administered, which substantially reduces the time and
burden associated with administration of PROs. Efforts are
under way to convert the IKDC-SKF to a CAT format that
is based on IRT.
Although computer-aided PRO assessment likely is the
future, further research for optimization of currently used
PROs is needed. Research should focus on determining the
most responsive items of current PROs to condense the
surveys to include only the most responsive questions. This
is important when considering the already collected PRO
data for tens of thousands of patients in large registries and
national databases. Such data might need to be reanalyzed
using the condensed PROs and thereby provide results with
a greater precision on clinically relevant outcomes.
Other important aspects for further research are out-
come measures on activity and RTS after ACL treatment.
Optimally, a tool that is able to quantify sports participa-
tion in terms of level, volume, and intensity should be
developed and implemented as a standardized tool used
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across studies. With the rapid evolution of technology, the
future will likely also hold easily accessible use of quanti-
tative instruments for quantitatively measuring patient
activity, for example, the use of Global Positioning System
and motion detectors during sports participation, measure-
ments of joint function, and measurements of heart rate
and speed to estimate intensity.
CONCLUSION
Clinical outcome assessment after ACL injury can be
divided in 4 robust categories: early adverse events, PROs,
ACL failure/recurrent ligament disruption, and clinical
measures of knee function and structure. A minimum of
2-year follow-up is necessary for a comprehensive and reli-
able determination of outcome, which should include out-
comes provided by clinical examination, PROs, and verified
reinjuries. The PRO assessment is a cornerstone in evalu-
ating outcome after ACL injury, where validated knee-
specific PRO assessment, HRQoL, and measure of type and
level of sport/activity should be collected. The IKDC-SKF is
the recommended knee-related PRO measure for ACL
treatment, and the use of PASS is encouraged to facilitate
interpretation of PROs.
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APPENDIX
Panther Consensus 2 Outcomes: Initial Survey Data
Answer choices: strongly agree, somewhat agree, neither agree nor disagree, somewhat disagree, strongly disagree
Q1. Short-term outcome assessment should include




Q2. Medium-term outcome assessment should include
a minimum 5 years and 80% follow-up of the entire cohort.
70% strongly agree
30% somewhat agree
Q3. Assessment of patient-reported outcome (PRO) should
include one knee-specific outcome tool, one activity rating




Q4. The International Knee Documentation Committee
Subjective Knee Form (IKDC-SKF) is the accepted knee-
related outcome measure for anterior cruciate ligament
(ACL) injury and surgery.
61% strongly agree
22% somewhat agree
13% neither agree nor disagree
4% strongly disagree
Q5. A single numerical measure is sufficient for assessing
overall outcome after ACL injury/surgery.
13% strongly agree
8% somewhat agree
29% neither agree nor disagree
25% somewhat disagree
25% strongly disagree
Q6. The evidence to support the interpretation and use of a
PRO for the knee should include:
 The minimum detectable change (MDC) score
 The minimal clinically important difference (MCID)
score
 The patient acceptable symptom state (PASS) score




13% neither agree nor disagree
Q7. After ACL surgery, short-term outcome assessment




Q8. After ACL surgery, medium- to long-term
outcome assessment (5 years) should include osteoarthri-
tis (OA) progression, PRO, and graft failure/reinjury.
64% strongly agree
36% somewhat agree
Q9. Rotatory knee laxity outcome should be assessed as an
outcome after ACL reconstruction.
33% strongly agree
54% somewhat agree
8% neither agree nor disagree
4% somewhat disagree
Q10. For acute injury, final functional status is the out-
come of interest, and minimum preoperative outcome
reporting must include demographic information and





Q11. For chronic injury, improvement from presurgery
status is the outcome of interest, and minimum preop-
erative outcome reporting must include full PRO assess-




Q12. For medium- to long-term outcome assessment
(5 years), OA progression is the outcome of interest, and
baseline radiographic status of the ipsilateral knee and
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4% neither agree nor disagree
13% somewhat disagree
4% strongly disagree
Q13. Sample sizes of 400 to 500 are required for studies




29% neither agree nor disagree
4% somewhat disagree
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